RHY (ASX) An opinion on the commercial prospects of RHY

Originally posted by Deme ↑

Sorry to hear about your shabby treatment in other threads. I am a big fan of the ignore function when posters make it personal.

Yes, AP really does look like a case of management incompetence.

As part of my due diligence, I was in contact with RHY's new CEO, Glenn, recently. We touched on the competitive landscape, costs, etc. You may wish to contact him for a chat. I'm sure he could answer all of your questions. My takeaway is that cost is definitely a critical factor in terms of the adoption of a new test within the industry (but equally so is the participation rate).

Have you read the Sprout8 note on RHY? http://sprout8.com/rhy-research-report/

It mentions potential government support to accelerate commercialisation (given the low participation rates of the FIT test). The government appears keen to have the at risk population segment undergo an annual test. So, the sell may not be as difficult as it seems.

Not sure re: Trevor. The Sprout8 note mentions that he voluntarily moved from CSIRO to continue the ColoSTAT project. His continued involvement & links with CSIRO are mentioned as being important. TBH, I was happy (and relieved) that Glenn was internally promoted to the new CEO position. He has the business acumen to transition the company towards commercialisation, whereas Trevor can focus on the science.

Expand

@Deme thanks for all this information. The Sprout8 note is overly optimistic, but it contains a lot of very interesting information that I assume came from their conversations with the company. This helps fill in a lot of gaps.

I do still think that there is a significant amount of risk the assay may fail in clinical testing, but if things works then they have some potential. I think it would be a good idea for RHY to undertake some formal market research to ensure they have a market. This would help support the SP during the sensitive time before clinical results are known.

I am putting RHY onto my watch list and if the clinical testing works I may invest.

No.	Vol.	Price($)
1	20000	6.5¢

No.

Vol.

Price($)

20000

6.5¢

Price($)	Vol.	No.
7.6¢	12800	1

Price($)

Vol.

No.

7.6¢

12800

No.	Vol.	Price($)
2	75525	0.063
1	16000	0.062
2	83639	0.060
2	38605	0.051
1	66665	0.045

No.

Vol.

Price($)

75525

0.063

16000

0.062

83639

0.060

38605

0.051

66665

0.045

Price($)	Vol.	No.
0.064	9245	1
0.065	51999	3
0.066	107305	1
0.067	195346	2
0.070	1794	1

Price($)

Vol.

No.

0.064

9245

0.065

51999

0.066

107305

0.067

195346

0.070

1794

(20min delay)
Last 6.4¢		Change 0.000(0.00%)		Mkt cap ! $15.41M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

An opinion on the commercial prospects of RHY, page-12

Buyers (Bids)

Sellers (Offers)